Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Neurotech International

  • Home
  •  
  • Neurotech International



  • Most Read
  • Latest Comments
  • Autism patient conditions improved after 12 weeks of treatment of Neurotech’s drug
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Autism patient conditions improved after 12 weeks of treatment of Neurotech’s drug
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Autism patient conditions improved after 12 weeks of treatment of Neurotech’s drug
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Autism patient conditions improved after 12 weeks of treatment of Neurotech’s drug
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Autism patient conditions improved after 12 weeks of treatment of Neurotech’s drug
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Zelira Therapeutics nears clinical trial stage for Autism drug following positive FDA feedback
    Zelira Therapeutics nears clinical trial stage for Autism drug following positive FDA feedback
    • News

  • Autism patient conditions improved after 12 weeks of treatment of Neurotech’s drug
    Autism patient conditions improved after 12 weeks of treatment of Neurotech’s drug
    • News

  • Clinical trial reveals promising outcomes for children with paediatric autoimmune neuropsychiatric disorders
    Clinical trial reveals promising outcomes for children with paediatric autoimmune neuropsychiatric disorders
    • News

  • Neurotech applies for ethics approval to trial cannabis as a treatment for Rett Syndrome
    Neurotech applies for ethics approval to trial cannabis as a treatment for Rett Syndrome
    • News

  • Neurotech reports clinical trial results for world first Autism Spectrum Disorder drug
    Neurotech reports clinical trial results for world first Autism Spectrum Disorder drug
    • News

  • Autism patient conditions improved after 12 weeks of treatment of Neurotech’s drug
    • News

    Autism patient conditions improved after 12 weeks of treatment of Neurotech’s drug

    Can you make autistic people less autistic? Neurotech International (ASX: NTI) believes so based on data published from their Phase II/III clinical trial of NTI-164 which aims to treat Autism Spectrum Disorder (ASD).  ASD is a complex neurodevelopmental condition that can manifest in various ways. From challenges in social interactions, repetitive behaviours, and restricted interests,

    Read More
    Public
  • Clinical trial reveals promising outcomes for children with paediatric autoimmune neuropsychiatric disorders
    • News

    Clinical trial reveals promising outcomes for children with paediatric autoimmune neuropsychiatric disorders

    PANDAS and PANS are debilitating conditions characterised by distressing symptoms, ranging from rage to signs of obsessive compulsive disorder.

    Read More
    Public
  • Neurotech applies for ethics approval to trial cannabis as a treatment for Rett Syndrome
    • News

    Neurotech applies for ethics approval to trial cannabis as a treatment for Rett Syndrome

    About one in 9,000 females in Australia are diagnosed with Rett Syndrome at birth. In the US, about 15,000 girls and women suffer from it, and globally, this number grows to 350,000 females. The significance of its prevalence is nothing compared to its impact. The disorder can have a detrimental effect on the lives of

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.